Adicet Bio Inc

Adicet Bio, Inc. is a clinical-stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company's pipeline is centered on 'off-the-shelf' gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead candidate, prulacabtagene leucel (prula-cel, formerly ADI-001), is being evaluated in a Phase 1 clinical trial across multiple autoimmune conditions including lupus nephritis, systemic lupus erythematosus, and systemic sclerosis. The company is also advancing ADI-212, a next-generation gene-edited, armored cell therapy candidate targeting PSMA for metastatic castration-resistant prostate cancer, which incorporates membrane-tethered IL-12 armoring and CRISPR/Cas9-mediated MED12 disruption. Additionally, Adicet is developing a differentiated in vivo CAR-T platform and pipeline targeting hematologic malignancies and solid tumors. The company is pre-revenue and trades on Nasdaq under the ticker ACET. Updated Aug 5, 2026